418 related articles for article (PubMed ID: 30334242)
1. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
Weiss J; Afghahi A; Shagisultanova E; Diamond JR
Oncology (Williston Park); 2018 Oct; 32(10):513-5. PubMed ID: 30334242
[No Abstract] [Full Text] [Related]
2. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Agostinetto E; Debien V; Marta GN; Lambertini M; Piccart-Gebhart M; de Azambuja E
Eur J Clin Invest; 2021 Jul; 51(7):e13535. PubMed ID: 33662161
[TBL] [Abstract][Full Text] [Related]
4. Palbociclib ups PFS in HER2-/ER+ breast cancer.
Cancer Discov; 2014 Jun; 4(6):624-5. PubMed ID: 24891344
[No Abstract] [Full Text] [Related]
5. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Mayer EL
Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
[No Abstract] [Full Text] [Related]
8. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
9. The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Eiger D; Wagner M; Pondé NF; Nogueira MS; Buisseret L; de Azambuja E
Acta Oncol; 2020 Jun; 59(6):723-725. PubMed ID: 32167397
[No Abstract] [Full Text] [Related]
10. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
Corona SP; Generali D
Drug Des Devel Ther; 2018; 12():321-330. PubMed ID: 29497278
[TBL] [Abstract][Full Text] [Related]
11. Targeting CDK4/6 pathways and beyond in breast cancer.
Ribnikar D; Volovat SR; Cardoso F
Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
[TBL] [Abstract][Full Text] [Related]
15. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
16. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
Figura NB; Potluri TK; Mohammadi H; Oliver DE; Arrington JA; Robinson TJ; Etame AB; Tran ND; Liu JK; Soliman H; Forsyth PA; Sahebjam S; Yu HM; Han HS; Ahmed KA
J Neurooncol; 2019 Sep; 144(3):583-589. PubMed ID: 31399935
[TBL] [Abstract][Full Text] [Related]
17. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
[TBL] [Abstract][Full Text] [Related]
18. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
19. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Sammons SL; Topping DL; Blackwell KL
Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]